Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2016-03-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
董事会关于2015年度证券投资情况的专项说明
Regulatory Filings Classification · 90% confidence The document is a detailed explanation from the board of directors of Jinling Pharmaceutical Co., Ltd. regarding the company's securities investment situation for the year 2015. It includes specific financial data such as investment amounts, gains, losses, and internal control measures related to securities investments. The document references prior quarterly reports where these matters were disclosed but itself focuses on a specific aspect of the company's financial activities rather than a full annual or quarterly report. The length is 3372 characters, which is relatively short but contains substantive financial data and analysis about securities investments. It is not an announcement of a report publication, nor a certification or a brief summary. The content aligns best with a specialized financial disclosure about securities investments, which fits under the category of Regulatory Filings (RNS) as it does not constitute a full annual or interim report, nor a standalone audit or earnings release. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2016-03-28 Chinese
关于2016年度日常关联交易预计情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expected related party transactions for the fiscal year 2016 by Jinling Pharmaceutical Co., Ltd. It includes detailed tables of estimated and actual transaction amounts with related parties, descriptions of the nature of these transactions, and independent directors' opinions on the fairness and compliance of these transactions. The document is titled as an "announcement" and is dated March 25, 2016. It does not contain comprehensive financial statements or a full financial report but rather focuses on disclosure of related party transactions and their expected amounts, which is typical for regulatory announcements related to ongoing related party dealings. This type of document fits best under the category of Regulatory Filings (RNS) as it is a regulatory disclosure announcement about related party transactions rather than a full annual report, interim report, or other specific report type.
2016-03-28 Chinese
2015年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2015 年度内部控制评价报告' which translates to '2015 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2015. The content includes detailed descriptions of internal control scope, evaluation criteria, defect classifications, and conclusions about the absence of major internal control deficiencies. The document is a standalone report focused on internal control evaluation, which aligns with the definition of an Audit Report / Information (AR) as it relates to internal control results and applied accounting principles. The document length is 4382 characters, which is sufficient to be a full report rather than a brief announcement. There is no indication that this is an announcement or a certification letter, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the best classification is AR (Audit Report / Information). FY 2015
2016-03-28 Chinese
2015年年度报告
Annual Report Classification · 100% confidence The document is titled as the 2015 Annual Report of Jinling Pharmaceutical Company Limited, covering the full year from January 1, 2015 to December 31, 2015. It includes detailed sections such as company overview, financial data, management discussion and analysis, business overview, and governance information. The length is substantial (15,000 characters), and it contains comprehensive financial performance data, management analysis, and business descriptions typical of an official yearly report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2015
2016-03-28 Chinese
2015年年度审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an audit report for the 2015 fiscal year of Jinling Pharmaceutical Co., Ltd. It contains detailed auditor responsibilities, management responsibilities, audit opinions, and extensive notes on accounting policies, financial statement preparation basis, and detailed financial disclosures. The presence of auditor signatures and the detailed financial statement notes indicate this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters), and it contains actual financial data and accounting policies, not just an announcement or certification. Therefore, it fits the category of an Audit Report / Information (AR). FY 2015
2016-03-28 Chinese
独立董事2015年度述职报告（王广基）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2015 Annual Report" and contains a detailed narrative of the independent director's duties, attendance at board meetings, opinions expressed, committee work, and efforts to protect shareholder rights during the 2015 fiscal year. It is a formal report by an independent director to shareholders, summarizing their activities and oversight for the year. This type of document is a management or board-related report rather than a full annual report or financial statement. It does not contain financial statements or audit opinions but focuses on governance and director duties. Therefore, it fits best under Board/Management Information (MANG), which covers announcements or reports related to board members and senior management activities.
2016-03-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.